SecBot SecBot

AKBA

Akebia Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001517022 Biotech & Drug Discovery
$0.4490 −0.03 (−5.27%)
Nov 16 4:00 PM ET · prev $0.4740
Market cap
$131.7M
Micro cap
Consensus
Buy
83% Buy or better · 12 analysts
Median target
$3.00
+568% · range $1.00–4.00
1 year
−74.5%
from $1.76 · Nov 17
30 days
−34.0%
from $0.6800
52-week range
$0.4010–1.76
−74% from high · low Nov 6
Avg volume 20D
8.75M
shares / day
Short interest
27.20M
≈9.8% of shares · +17.9%
Days to cover
3.0
at average volume
Insider net
−$876.4K
1 buyer · 6 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 3 bearish · 1 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $86.6K at an average $1.25. 6 insiders sold $963.0K. Price is 64% below their cost.

  • InstitutionsBEARISH

    Q3 2026: 13 added (0 new), 26 trimmed or exited.

  • AnalystsBULLISH

    10 of 12 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +17.9% to 27.20M shares. 3.0 days to cover, ≈9.8% of shares.

  • TrendDOWNTREND

    41% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 5.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD PORTFOLIO MANAGEMENT LLCADD3,537,072$3.3M
RENAISSANCE TECHNOLOGIES LLCADD1,883,909$1.7M
Qube Research & Technologies LtdTRIM785,126$722.3K
ALPS ADVISORS INCADD364,094$335.0K
MORGAN STANLEYTRIM306,882$282.3K
IEQ CAPITAL, LLCADD147,574$135.8K
Creative PlanningNEAR_EXIT135,515$124.7K
JPMORGAN CHASE & COTRIM136,555$121.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 83% rate it Buy or better
Strong Buy4Buy6Hold2Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +568%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Nov 6, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 5, 2026BTIG
MAINTAIN
MAINTAINBuy
Sep 15, 2026BTIG
REITERATE
REITERATEBuy
Sep 8, 2026WestPark Capital
INITIATE
INITIATEBuy
Aug 7, 2026Leerink Partners
DOWNGRADE
DOWNGRADEMarket Perform

Washington

Corporate Lobbying

24 lobbying filings and 4 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$86.6K
bought · 1 insider
$963.0K
sold · 6 insiders
−64.1%
vs their $1.25 cost
DateInsiderTypeValue
Aug 6, 2026
Butler John P.
CEO and President
Aug 6, 2026
EXERCISE$220.5K
Jun 29, 2026
Ostrowski Erik
SVP, CFO, CBO & Treasurer
Jun 29, 2026
SELL$62.2K
Jun 17, 2026
ADAMS ADRIAN
Director
Jun 17, 2026
AWARD53,600 sh
Jun 17, 2026
ZUMWALT LEANNE M
Director
Jun 17, 2026
AWARD35,700 sh
Jun 17, 2026
ADAMS ADRIAN
Director
Jun 17, 2026
AWARD35,700 sh
Jun 17, 2026
ZUMWALT LEANNE M
Director
Jun 17, 2026
AWARD53,600 sh
Jun 17, 2026
FRIESON RON
Director
Jun 17, 2026
AWARD35,700 sh
Jun 17, 2026
FRIESON RON
Director
Jun 17, 2026
AWARD53,600 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
27,204,975
shares short
+17.9%
vs prior settlement
3.0
days to cover
≈9.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Press
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Contract
🔒 Fresh data, subscribers only
Nov 5, 2026 SEC
Akebia reported Q3 2026 total revenue of $36.9M, down 37% YoY from $58.8M, driven by a 53% decline in Auryxia revenue…
8-K · Impact 5/10
Nov 5, 2026 SEC
Akebia reported Q3 2026 total revenue of $36.9M, down 37% YoY from $58.8M, driven by a 53% decline in Auryxia revenue…
PRESS-RELEASE · Impact 5/10
Oct 26, 2026 Press
Akebia Therapeutics announced positive VOICE trial data for Vafseo (vadadustat) presented at ASN Kidney Week, showing…
Impact 6/10
Sep 30, 2026 Inst.
VANGUARD PORTFOLIO MANAGEMENT LLC · ADD
3,537,072 shares ($3.3M)
Sep 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC · ADD
1,883,909 shares ($1.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent

SecBot reports

9 filings · 2 press releases · 2 bullish · 3 bearish · 1 mixed · 3 neutral
All AKBA filing & press-release reports (11)